Security
Invivyd, Inc. Common Stock · IVVD
IVVDNASDAQCommon stockCurrentCIK 1832038Updated Oct 6, 2026
Name history
Adagio Therapeutics, Inc. · through Sep 12, 2022
IVVD price & chart
Loading TradingView…
NASDAQ:IVVD on TradingView ↗About the company
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
In the news
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 ↗
Seeking Alpha
Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript ↗
Invivyd drops after delaying late-stage trial data for COVID therapy ↗
Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission - Slideshow ↗
Recent filings
Other Events
Items 8.01, 9.01
4 filing
3 filing
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 139,158,000Source | 161,922,000Source | 218,883,000Source | 89,138,000Source | 177,346,000Source | 241,742,000Source | 103,744,000Source | 215,468,000Source | 276,883,000Source | 129,515,000Source | 229,181,000Source | 383,167,000Source |
| Property, Plant and Equipment, NetUSD | 1,260,000Source | 1,640,000Source | 2,183,000Source | 1,392,000Source | 1,772,000Source | 1,693,000Source | 1,523,000Source | 1,901,000Source | 1,365,000Source | 1,508,000Source | 1,896,000Source | 2,282,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 84,967,000Source | 106,869,000Source | 160,080,000Source | 34,905,000Source | 147,881,000Source | 184,153,000Source | 48,078,000Source | 189,388,000Source | 226,689,000Source | 69,349,000Source | 200,641,000Source | 92,076,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 9,852,000Source | 8,154,000Source | 11,222,000Source | 8,698,000Source | 2,888,000Source | 11,648,000Source | 8,561,000Source | — | 13,919,000Source | 10,906,000Source | — | — |
| Inventory, NetUSD | 25,395,000Source | 27,067,000Source | — | 25,440,000Source | 5,333,000Source | — | 25,419,000Source | 109,000Source | — | 25,907,000Source | — | — |
| Assets, CurrentUSD | 109,769,000Source | 151,101,000Source | 182,112,000Source | 59,281,000Source | 173,011,000Source | 204,915,000Source | 75,825,000Source | 209,883,000Source | 247,467,000Source | 100,681,000Source | 224,881,000Source | 376,917,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 14,950,000Source | 9,011,000Source | 10,810,000Source | 15,678,000Source | 16,909,000Source | 9,114,000Source | 19,186,000Source | 20,386,000Source | 6,859,000Source | 20,426,000Source | 24,240,000Source | 4,926,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,728,000Source | 1,729,000Source | 8,067,000Source | 3,010,000Source | 782,000Source | 8,526,000Source | 953,000Source | 1,827,000Source | 2,442,000Source | 1,385,000Source | 2,229,000Source | 3,777,000Source |
| Other Assets, NoncurrentUSD | 6,000Source | 7,452,000Source | 1,176,000Source | 15,000Source | 1,781,000Source | 1,156,000Source | 24,000Source | 1,857,000Source | 110,000Source | 34,000Source | 175,000Source | 191,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 46,090,000Source | 78,761,000Source | 37,803,000Source | 46,349,000Source | 36,704,000Source | 38,692,000Source | 49,595,000Source | 36,970,000Source | 35,343,000Source | 61,976,000Source | 51,713,000Source | 27,197,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 22,000Source | 12,000Source | 29,000Source | 12,000Source | 12,000Source | 28,000Source | 12,000Source | 12,000Source | 28,000Source | 12,000Source | 11,000Source | 11,000Source |
| Retained Earnings (Accumulated Deficit)USD | -943,413,000Source | -883,551,000Source | -1,040,276,000Source | -932,943,000Source | -822,812,000Source | -995,883,000Source | -918,283,000Source | -775,565,000Source | -954,483,000Source | -901,994,000Source | -732,069,000Source | -533,426,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -41,000Source | -18,000Source | -35,000Source | -39,000Source | -12,000Source | -37,000Source | -13,000Source | -12,000Source | -41,000Source | -5,000Source | -13,000Source | -272,000Source |
| Stockholders' Equity Attributable to ParentUSD | 93,068,000Source | 83,161,000Source | 181,080,000Source | 42,789,000Source | 140,642,000Source | 203,050,000Source | 54,149,000Source | 178,498,000Source | 241,540,000Source | 67,539,000Source | 177,468,000Source | 355,970,000Source |
| Additional Paid in Capital, Common StockUSD | 1,036,500,000Source | 966,718,000Source | 1,221,362,000Source | 975,759,000Source | 963,454,000Source | 1,198,942,000Source | 972,433,000Source | 954,063,000Source | 1,196,036,000Source | 969,526,000Source | 909,539,000Source | 889,657,000Source |
| Liabilities and EquityUSD | 139,158,000Source | 161,922,000Source | 218,883,000Source | 89,138,000Source | 177,346,000Source | 241,742,000Source | 103,744,000Source | 215,468,000Source | 276,883,000Source | 129,515,000Source | 229,181,000Source | 383,167,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 44,496,000Source | 78,542,000Source | 31,028,000Source | 44,451,000Source | 36,704,000Source | 31,658,000Source | 49,595,000Source | 36,345,000Source | 34,163,000Source | 61,976,000Source | 50,291,000Source | 25,031,000Source |
| Operating Lease, Liability, CurrentUSD | 1,083,000Source | 1,414,000Source | 1,616,000Source | 1,067,000Source | 681,000Source | 1,592,000Source | 894,000Source | 1,134,000Source | 1,314,000Source | 1,304,000Source | 1,443,000Source | 1,559,000Source |
| Accounts Payable, CurrentUSD | 18,104,000Source | 17,707,000Source | 9,486,000Source | 18,051,000Source | 7,499,000Source | 2,022,000Source | 8,739,000Source | 1,168,000Source | 13,744,000Source | 10,448,000Source | 7,953,000Source | 1,517,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,594,000Source | 219,000Source | 6,775,000Source | 1,898,000Source | 0Source | 7,034,000Source | 0Source | 625,000Source | 1,180,000Source | 0Source | 722,000Source | 2,165,000Source |
| Other Liabilities, NoncurrentUSD | — | 0Source | — | — | 0Source | — | — | 0Source | — | 0Source | 700,000Source | 0Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 25,277,000Source | 59,401,000Source | 19,855,000Source | 25,307,000Source | 26,822,000Source | 27,988,000Source | 39,928,000Source | 34,003,000Source | 19,053,000Source | 50,197,000Source | 40,860,000Source | 21,911,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -41,400,000Source | -16,289,000Source | -52,489,000Source | -169,925,000Source | -198,643,000Source | -241,317,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,697,000Source | 2,826,000Source | 11,643,000Source | 19,788,000Source | 18,685,000Source | 21,648,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -2,221,000Source | -2,345,000Source | 3,337,000Source | 10,906,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -47,000Source | 58,000Source | 373,000Source | 24,889,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -11,566,000Source | -1,637,000Source | 3,211,000Source | 2,423,000Source | 6,471,000Source | -4,300,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -41,712,000Source | -21,129,000Source | -58,135,000Source | -170,491,000Source | -173,164,000Source | -219,987,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -726,000Source | -144,000Source | -155,000Source | -140,000Source | 280,684,000Source | -230,667,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 726,000Source | 144,000Source | 155,000Source | 140,000Source | 615,000Source | 1,705,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | 0Source | 1,000Source | 4,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -98,000Source | 10,000Source | 215,630,000Source | 39,331,000Source | 1,045,000Source | 506,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -42,536,000Source | -21,271,000Source | 157,340,000Source | -131,292,000Source | 108,565,000Source | -450,148,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 84,967,000Source | 106,869,000Source | 160,080,000Source | 34,905,000Source | 184,153,000Source | 48,078,000Source | 226,689,000Source | 69,349,000Source | 200,641,000Source | 92,076,000Source |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | — | — | — | — | — | — | — | — | — | 280,187,000Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,073,000Source | 2,866,000Source | 2,895,000Source | 3,180,000Source | 2,697,000Source | 2,826,000Source | 11,643,000Source | 19,788,000Source | 18,685,000Source | 21,648,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | — | 480,000Source | 41,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -10,470,000Source | -60,739,000Source | -44,393,000Source | -14,660,000Source | -41,400,000Source | -16,289,000Source | -52,489,000Source | -169,925,000Source | -198,643,000Source | -241,317,000Source |
| Nonoperating Income (Expense)USD | — | — | 553,000Source | 1,572,000Source | 1,427,000Source | 400,000Source | 1,736,000Source | 633,000Source | 3,071,000Source | 6,951,000Source | 14,115,000Source | 6,714,000Source |
| Operating ExpensesUSD | — | — | — | — | 60,105,000Source | 26,846,000Source | 56,880,000Source | 28,226,000Source | 108,986,000Source | 202,260,000Source | 212,758,000Source | 248,031,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 135,000Source | 44,000Source | 254,000Source | 223,000Source | 240,000Source | 269,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 74,000Source | 37,000Source | 411,000Source | 420,000Source | 955,000Source | 241,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 13,129,000Source | 9,300,000Source | 14,285,000Source | 11,786,000Source | 13,744,000Source | 11,304,000Source | 53,426,000Source | 25,384,000Source | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 15,018,000Source | 12,955,000Source | 29,465,000Source | 16,588,000Source | 25,117,000Source | 16,751,000Source | 66,931,000Source | 63,388,000Source | 49,125,000Source | 47,044,000Source |
| Operating Income (Loss)USD | — | — | -11,023,000Source | -62,311,000Source | -45,820,000Source | -15,060,000Source | -43,136,000Source | -16,922,000Source | -55,560,000Source | -176,876,000Source | -212,758,000Source | -248,031,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -10,470,000Source | -60,739,000Source | -44,393,000Source | -14,660,000Source | -41,400,000Source | -16,289,000Source | -52,489,000Source | -169,925,000Source | -198,643,000Source | -241,317,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.06Source | -0.51Source | -0.14Source | -0.12Source | -0.13Source | -0.14Source | -0.3Source | -1.43Source | -1.81Source | -2.23Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.06Source | -0.51Source | -0.14Source | -0.12Source | -0.13Source | -0.14Source | -0.3Source | -1.43Source | -1.81Source | -2.23Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 170,169,865Source | 119,495,284Source | 320,435,078Source | 120,016,132Source | 309,670,101Source | 119,883,479Source | 172,212,902Source | 118,555,073Source | 109,526,053Source | 108,268,289Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 170,169,865Source | 119,495,284Source | 320,435,078Source | 120,016,132Source | 309,670,101Source | 119,883,479Source | 172,212,902Source | 118,555,073Source | 109,526,053Source | 108,268,289Source |
| Additional Financial Items | ||||||||||||
| Cost, Depreciation and AmortizationUSD | — | — | — | — | — | — | 168,000Source | 306,000Source | 755,000Source | 1,466,000Source | — | — |
| Costs and ExpensesUSD | — | — | 24,152,000Source | 71,611,000Source | 60,105,000Source | 26,846,000Source | 56,880,000Source | 28,226,000Source | 108,986,000Source | 202,260,000Source | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 554,000Source | 1,563,000Source | 1,503,000Source | 405,000Source | — | 628,000Source | 3,107,000Source | 7,216,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 553,000Source | 1,572,000Source | 1,427,000Source | 400,000Source | 1,736,000Source | 633,000Source | 3,071,000Source | 6,951,000Source | 14,115,000Source | 6,714,000Source |
| Operating ExpensesUSD | — | — | — | — | 60,105,000Source | 26,846,000Source | 56,880,000Source | 28,226,000Source | 108,986,000Source | 202,260,000Source | 212,758,000Source | 248,031,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
| Research and Development ExpenseUSD | — | — | 8,046,000Source | 57,850,000Source | 29,367,000Source | 9,573,000Source | 30,731,000Source | 10,641,000Source | 38,308,000Source | 137,254,000Source | 158,658,000Source | 179,214,000Source |
Filing attachments
ivvd-ex99_1.htm · 8-K · 2026-09-29
Exhibit 99.1 Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 • VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and tolerability of an mRNA-based COVID-19 vaccine • VYD2311 combine…
Read attachment ↗ivvd-ex99_2.htm · 8-K · 2026-09-29
Topline LIBERTY Data & VYD2311 Next Steps September 29, 2026 ©2026 Invivyd, Inc. Invivyd is a registered trademark of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners. Exhibit 99.2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forwa…
Read attachment ↗ivvd-ex99_1.htm · 8-K · 2026-09-01
EX-99.1 3 ivvd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY • Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategy • Ajay Royan, Founder of Mithril Capital and a founding, long-term investor in Invivyd, appointed Lead Independent Director • Ian Sheffield appointed to Invivyd’…
Read attachment ↗ivvd-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 ivvd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Achieved Q2 2026 PEMGARDA® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million • Completed rapid enrollment in VYD2311 DECLARATION clinical trial expansion cohort and LIBERTY clinical trial, driven by strong subject demand • DECLARATION pivotal clinical trial enrollment is …
Read attachment ↗ivvd-ex99_1.htm · 8-K · 2026-07-06
EX-99.1 2 ivvd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA • U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the COVID-19 EUA declaration, effective June 29, 2027 • Consequently, Invivyd received from the U.S. Food and Drug Administration (FDA) Notice of Termination of t…
Read attachment ↗d120795dex991.htm · 8-K · 2026-05-14
EX-99.1 2 d120795dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 million Invivyd in vitro data showed continued neutralizing activity of pemivibart and VYD2311 against SARS-CoV-2 variant BA.3.2.2 (“Cicada”), confirming anticipated activity DECLARATION trial Ind…
Read attachment ↗